Posted by Michael Wonder on 13 Jul 2016
Pfizer receives FDA approval for Prevnar 13 in adults age 18 through 49
12 July 2016 - Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthood.
Pfizer today announced that Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. FDA approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13 is the only pneumococcal vaccine approved across the lifespan.
